Selective COX-2 inhibitors suppress prostacyclin

Clinical Therapeutics

Volumn 36, Issue 12, 2014, Pages 2120-2121

  Skarke, Carsten ^a   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; POLMACOXIB; PROSTACYCLIN; PROSTAGLANDIN E2; FURAN DERIVATIVE; SULFONAMIDE;

COMPETITIVE INHIBITION; CROSS REACTION; DRUG HALF LIFE; DRUG SELECTIVITY; ENZYME INHIBITION; ERYTHROCYTE; HUMAN; LETTER; PEROXIDATION; FEMALE; MALE;

CYCLOOXYGENASE 2 INHIBITORS; FEMALE; FURANS; HUMANS; MALE; SULFONAMIDES;

EID: 84916937477     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.09.024     Document Type: Letter

References (5)

1. Kim MJ, Lim HS, Jin S, et al. Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase I, randomized, multiple-dose study in healthy Korean men and women. Clin Ther. 2014 Aug 7. [Epub ahead of print.
2. Skarke C, Alamuddin N, Lawson JA, et al. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther. 2012;91:986-993.
3. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986-1000.
4. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272-277.
5. Grosser T, Yu Y, FitzGerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med. 2010;61:17-33.